Analysts Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Target Price at $17.25

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have earned a consensus recommendation of “Moderate Buy” from the five brokerages that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $17.25.

ENTA has been the subject of a number of research reports. Robert W. Baird reduced their price objective on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a research report on Tuesday, November 26th. HC Wainwright reduced their price target on shares of Enanta Pharmaceuticals from $27.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, December 24th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $21.00 price objective (down previously from $22.00) on shares of Enanta Pharmaceuticals in a research note on Tuesday, November 26th.

Enanta Pharmaceuticals Stock Performance

NASDAQ ENTA opened at $6.01 on Thursday. Enanta Pharmaceuticals has a one year low of $5.70 and a one year high of $17.80. The stock has a 50-day moving average of $9.15 and a 200 day moving average of $11.47. The company has a market capitalization of $127.38 million, a price-to-earnings ratio of -1.10 and a beta of 0.49.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.20). Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. The company had revenue of $14.60 million for the quarter, compared to the consensus estimate of $17.99 million. During the same quarter last year, the company earned ($1.33) EPS. The firm’s revenue for the quarter was down 22.8% on a year-over-year basis. On average, equities analysts predict that Enanta Pharmaceuticals will post -4.73 earnings per share for the current fiscal year.

Insider Buying and Selling at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 5,142 shares of the company’s stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $8.06, for a total value of $41,444.52. Following the completion of the transaction, the chief executive officer now directly owns 801,638 shares in the company, valued at $6,461,202.28. This represents a 0.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 13.64% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. JPMorgan Chase & Co. boosted its stake in Enanta Pharmaceuticals by 53.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 243,628 shares of the biotechnology company’s stock worth $2,524,000 after purchasing an additional 85,082 shares during the period. Barclays PLC boosted its position in shares of Enanta Pharmaceuticals by 294.2% during the third quarter. Barclays PLC now owns 27,438 shares of the biotechnology company’s stock worth $285,000 after acquiring an additional 20,478 shares during the last quarter. Geode Capital Management LLC grew its stake in Enanta Pharmaceuticals by 3.1% during the third quarter. Geode Capital Management LLC now owns 477,351 shares of the biotechnology company’s stock valued at $4,946,000 after acquiring an additional 14,575 shares in the last quarter. Krensavage Asset Management LLC increased its holdings in Enanta Pharmaceuticals by 19.7% in the 3rd quarter. Krensavage Asset Management LLC now owns 1,498,074 shares of the biotechnology company’s stock valued at $15,520,000 after acquiring an additional 246,736 shares during the last quarter. Finally, Wellington Management Group LLP bought a new position in shares of Enanta Pharmaceuticals during the 3rd quarter valued at about $360,000. Hedge funds and other institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.